We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01096602
Recruitment Status : Active, not recruiting
First Posted : March 31, 2010
Last Update Posted : January 10, 2023
National Institutes of Health (NIH)
Medivation, Inc.
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Jacalyn Rosenblatt, MD, Dana-Farber Cancer Institute

Brief Summary:
Acute myelogenous leukemia (AML) arises from leukemia stem cells that are difficult to eradicate and serve as a reservoir for disease relapse following chemotherapy. A promising area of investigation is the development of immunotherapeutic approaches that stimulate the immune system to recognize leukemia stem cells as foreign and eliminate them. The purpose of this research study is to determine the safety of the Dendritic Cell AML Fusion Vaccine (DC AML vaccine) after participants have achieved a remission with chemotherapy. In this clinical trial, patients are treated with a tumor vaccine alone following standard of care chemotherapy. The DC AML vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. It is hoped that DC AML vaccine will prevent or delay the disease from coming back.

Condition or disease Intervention/treatment Phase
Acute Myelogenous Leukemia AML Biological: DC AML Vaccine Phase 2

Detailed Description:
  • On this study participants will receive the DC AML vaccine and GM-CSF 4-8 weeks after completion of chemotherapy for acute myelogenous leukemia (AML). GM-CSF is a drug that stimulates white blood cells and is given with the DC AML Vaccine in an effort to enhance the effect of the vaccine. Participants will receive 2-3 doses of the vaccine at 4 week intervals.
  • All participants will undergo the following procedures: Isolation of tumor cells by either bone marrow biopsy or blood draw; Initial chemotherapy for AML with standard therapy; Leukopheresis (collection of white blood cells from the blood).
  • All participants will also have blood tests, a physical exam, and an electrocardiogram prior to each dose of vaccine.
  • Four weeks following the final vaccination, participants will undergo a skin test called "delayed-type hypersensitivity" (DTH). This is an injection of the tumor cells under the skin to measure how the immune system responds. The tumor cells are broken up and irradiated to prevent their growth.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Study Start Date : May 2010
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : June 2024

Arm Intervention/treatment
Experimental: Group 1
DC AML Fusion Vaccine
Biological: DC AML Vaccine
Group 1: 2-3 doses of the vaccine at 4 week intervals

Primary Outcome Measures :
  1. Toxicity [ Time Frame: 2 years ]
    To assess the toxicity associated with treating AML patients with DC/AML fusion cells in the post-chemotherapy setting

Secondary Outcome Measures :
  1. Immune Response [ Time Frame: 2 years ]
    To explore immunological response to DC/AML fusion vaccination in patients who have achieved a chemotherapy-induced remission.

  2. T-cell and Immune Response [ Time Frame: 2 years ]
    To correlate levels of circulating activated and regulatory T cells with immunologic response

  3. Disease Response [ Time Frame: 2 years ]
    To define anti-tumor effects by determining time to disease progression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  • Patients with AML at initial diagnosis or at first relapse
  • 18 years of age or older
  • ECOG Performance Status 0-2
  • Life expectancy of greater than 9 weeks
  • Laboratory values within limits outlined in the protocol
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

Prior to Cell Collections for Dendritic Cell Generation:

  • Patients must have obtained complete remission with chemotherapy defined by the absence of circulating blasts, and less then 5% blasts on bone marrow examination following hematopoietic recovery
  • Resolution of all chemotherapy related Grade III-IV toxicity as per CTC criteria 4.0
  • Laboratory values as outlined in the protocol
  • For patients with evidence of minimal residual disease prior to vaccination, assessment of minimal residual disease status by cytogenetics or FISH will be followed post vaccination

Prior to Post-Chemotherapy Immunotherapy:

  • Resolution of all chemotherapy related grade III-IV toxicity
  • Laboratory values as outlined in the protocol
  • At least 2 doses of fusion vaccine produced

Exclusion Criteria:


  • Active or history of autoimmune disorders/conditions including Type 1 diabetes. Type II diabetes, vitiligo or stable hyperthyroidism will not be considered exclusion criteria
  • HIV positive
  • Significant cardiac disease characterized by symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia
  • Pregnant women
  • Individuals with a history of a different malignancy are ineligible except for circumstances outlined in the protocol document

Prior to Cell Collection for Dendritic Cell Generation:

  • Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
  • Patients who choose to proceed with allogeneic or autologous transplant at the time of remission will not be vaccinated and will come off study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096602

Layout table for location information
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
National Institutes of Health (NIH)
Medivation, Inc.
The Leukemia and Lymphoma Society
Layout table for investigator information
Principal Investigator: Jacalyn Rosenblatt, MD Beth Israel Deaconess Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jacalyn Rosenblatt, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01096602    
Other Study ID Numbers: 09-412
First Posted: March 31, 2010    Key Record Dates
Last Update Posted: January 10, 2023
Last Verified: January 2023
Keywords provided by Jacalyn Rosenblatt, MD, Dana-Farber Cancer Institute:
Dendritic Cell/AML vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type